Radiosensitization of NET cells by HSP90 inhibitor ganetespib is mediated through pleiotropic stress responses.

ABSTRACT:

Background

Peptide receptor radionuclide therapy (PRRT) employing [¹⁷⁷Lu]Lu-[DOTA-Tyr³]octreotate has been established as treatment for patients with metastatic neuroendocrine tumors (NETs) that overexpress the somatostatin receptor (SSTR). While PRRT improves survival and quality of life, curative responses remain rare. One way to enhance PRRT efficacy is to combine it with radiosensitizing agents such as heat shock protein 90 (HSP90) inhibitors. HSP90 is a highly conserved molecular chaperone essential for the maturation and stabilization of over a hundred proteins, including proteins involved in the DNA damage response and oncogenic signaling. HSP90-inhibition has been shown to potentiate PRRT, however the mechanism behind this radiosensitizing effect remai

SUBMITTER: Engbers PAM 

PROVIDER: S-EPMC12748489 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature